REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Testing for oligoclonal Ig bands in cerebrospinal fluid is useful in predicting which patients with clinically isolated syndrome (CIS) are at risk of developing clinically-definite MS (Tumani et al. ECTRIMS 2014; abstract P197). Read More
Latest News
Trend to earlier, more aggressive therapy: U.S. survey
September 11, 2014REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – A U.S. survey of academic and community neurologists from the Consortium of Multiple Sclerosis Centers (CMSC) reports that clinicians tend to favour an earlier, more aggressive treatment approach (Tornatore et al. ECTRIMS 2014; abstract P295). Read More
Novel theory proposed for AD
September 3, 2014Researchers in Texas have proposed that vascular activation contributes to the pathogenesis of Alzheimer’s disease, resulting in the overexpression of amyloid-beta and other factors (Grammas et al. J Alzheimers Dis 2014;40:619-630). Read More
Atacicept: the aftermath
September 3, 2014The debate about the relative importance of T cells and B cells in the pathogenesis of MS will be refueled with the long-awaited publication of the results of the failed ATAMS study of atacicept (Kappos et al. Lancet Neurol 2014;13:353-363). Preliminary results from the two atacicept studies, ATAMS in relapsing MS and ATON in optic neuritis, were presented at ECTRIMS 2011 (Kappos et al. Abstract 107; Sergott et al. Abstract P436) and signalled the death knell for the drug in MS. Read More